Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
DXR 
Daxor Corporation (DXR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: DXR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $23.5
1 Year Target Price $23.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -8.7% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 56.27M USD | Price to earnings Ratio - | 1Y Target Price 23.5 |
Price to earnings Ratio - | 1Y Target Price 23.5 | ||
Volume (30-day avg) 2 | Beta -0.13 | 52 Weeks Range 6.55 - 11.38 | Updated Date 08/28/2025 |
52 Weeks Range 6.55 - 11.38 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.09 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 448.01% | Operating Margin (TTM) -2368.66% |
Management Effectiveness
Return on Assets (TTM) -2.51% | Return on Equity (TTM) 1.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 42930072 | Price to Sales(TTM) 470.05 |
Enterprise Value 42930072 | Price to Sales(TTM) 470.05 | ||
Enterprise Value to Revenue 26.61 | Enterprise Value to EBITDA - | Shares Outstanding 4962240 | Shares Floating 2126830 |
Shares Outstanding 4962240 | Shares Floating 2126830 | ||
Percent Insiders 56.9 | Percent Institutions 2.19 |
Upturn AI SWOT
Daxor Corporation
Company Overview
History and Background
Daxor Corporation was founded in 1971. It focuses on blood volume measurement technology, specifically using its BVA-100 instrument. The company has evolved from research to commercializing its BVA technology.
Core Business Areas
- Blood Volume Analysis (BVA): Daxor's primary focus is on Blood Volume Analysis (BVA) using its BVA-100 instrument. BVA helps clinicians optimize fluid management in patients with various medical conditions.
- Reagent Kits: Daxor also sells reagent kits that are required for the BVA tests. These kits are a recurring revenue stream for the company.
- BVA-100 Instrument Services: Daxor provides services related to the installation, training, maintenance and repair of the BVA-100 instrument.
Leadership and Structure
Daxor's leadership includes the CEO and a team of executives overseeing various departments such as sales, marketing, and R&D. The organizational structure is typical of a small medical device company.
Top Products and Market Share
Key Offerings
- BVA-100 (Blood Volume Analyzer): The BVA-100 is Daxor's flagship product, measuring a patient's blood volume. Market share data is not readily available, as it's a niche market. The number of users is limited to hospitals and clinics that have adopted the technology. Revenue information is available in their financial reports. Competitors include companies offering indirect blood volume assessment methods, which are less precise (e.g., clinical assessment, central venous pressure monitoring).
- BVA Reagent Kits: Reagent kits are used with the BVA-100 and provide the necessary materials for performing blood volume analysis. These kits generate recurring revenue for Daxor. The market size is directly proportional to the BVA-100 install base. Competitors are other manufacturers of reagents for diagnostic testing, though specifically for blood volume analysis, Daxor has a significant advantage due to its instrument.
Market Dynamics
Industry Overview
The industry involves blood volume measurement for clinical applications. There's increasing recognition of the importance of personalized fluid management. The growth is moderate as BVA remains a relatively specialized test.
Positioning
Daxor is a niche player with a unique technology (BVA-100). Its competitive advantage lies in the accuracy and direct measurement of blood volume, which differentiates it from indirect methods.
Total Addressable Market (TAM)
The TAM for blood volume analysis is estimated to be hundreds of millions of dollars, considering the potential applications in various clinical settings. Daxor is well-positioned to capture a share of this market with its specialized BVA technology.
Upturn SWOT Analysis
Strengths
- Proprietary BVA-100 technology
- Accuracy in blood volume measurement
- Recurring revenue from reagent kits
- Established reputation in its niche
Weaknesses
- Limited market awareness of BVA
- Relatively small sales and marketing team
- High reliance on a single product (BVA-100)
- Financial constraints
Opportunities
- Expanding applications of BVA in heart failure, sepsis, and kidney disease
- Partnerships with hospitals and clinics
- Increased awareness of personalized medicine
- Geographic expansion
Threats
- Competition from indirect blood volume assessment methods
- Changes in clinical guidelines
- Technological advancements by competitors
- Economic downturns affecting hospital budgets
Competitors and Market Share
Key Competitors
- Edwards Lifesciences (EW)
- ICU Medical (ICUI)
Competitive Landscape
Daxor's advantage is its direct BVA measurement. Disadvantages include smaller size and market reach compared to larger medical device companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been variable, depending on the sales of the BVA-100. Growth has been modest overall.
Future Projections: Future growth projections depend on market adoption of BVA technology and expansion into new clinical areas. Analyst estimates are necessary for a detailed forecast.
Recent Initiatives: Recent initiatives could include new partnerships, product enhancements, or marketing campaigns to promote BVA.
Summary
Daxor Corporation is a niche medical device company with proprietary BVA technology. Its strengths include accurate blood volume measurement and recurring revenue from reagent kits. Weaknesses include limited market awareness and reliance on a single product. The company should focus on expanding applications of BVA and building partnerships to drive future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Daxor Corporation SEC Filings (10-K, 10-Q), Company Website, Industry Reports, Analyst Reports
Disclaimers:
The information provided is based on available data and analysis and is not financial advice. Market share estimates are approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Daxor Corporation
Exchange NASDAQ | Headquaters Oak Ridge, TN, United States | ||
IPO Launch date 1992-03-17 | Chairman, President & CEO Mr. Michael Richard Feldschuh | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees - | Website https://www.daxor.com |
Full time employees - | Website https://www.daxor.com | ||
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.